Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3FXYD2
The experimentally established mechanism targets of Deslanoside. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 13/20 | 0.80 |
| ▸ | ATP1B1 known ✓ | P05026 | 13/20 | 0.80 |
| ▸ | ATP1B2 known ✓ | P14415 | 13/20 | 0.80 |
| ▸ | ATP1A2 known ✓ | P50993 | 13/20 | 0.80 |
| ▸ | ATP1B3 known ✓ | P54709 | 13/20 | 0.80 |
| ▸ | ATP1A3 known ✓ | P13637 | 5/20 | 0.80 |
| ▸ | FXYD2 known ✓ | P54710 | 5/20 | 0.80 |
| ▸ | ATP1A4 known ✓ | Q13733 | 5/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.89 |
| ▸ | TP53 | P04637 | 3/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.89 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.89 |
| ▸ | THRB | P10828 | 1/20 | 0.89 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | GLA | P06280 | 1/20 | 0.80 |
| ▸ | STAT3 | P40763 | 1/20 | 0.80 |
| ▸ | RECQL | P46063 | 1/20 | 0.80 |
| ▸ | RAB9A | P51151 | 1/20 | 0.80 |
| ▸ | RORC | P51449 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deslanoside SCHEMBL125311 | 1.00 | MAPT (1.00) | MAPTLMNATP53SMN1; SMN2PAX8 | |
| Deslanoside SCHEMBL12840817 | 1.00 | MAPT (1.00) | MAPTLMNATP53SMN1; SMN2PAX8 | |
| Deslanoside SCHEMBL28142803 | 0.97 | MAPT (0.95) | MAPTLMNATP53SMN1; SMN2PAX8 | |
| Deslanoside SCHEMBL10633059 | 0.96 | MAPT (0.92) | MAPTLMNATP53SMN1; SMN2PAX8 | |
| Lanatoside C SCHEMBL23054706 | 0.94 | PAX8 (1.00) | MAPTLMNATP53SMN1; SMN2PAX8 | |
| Lanatoside C SCHEMBL15959375 | 0.94 | PAX8 (1.00) | MAPTLMNATP53SMN1; SMN2PAX8 | |
| Lanatoside C SCHEMBL18947801 | 0.94 | PAX8 (1.00) | MAPTLMNATP53SMN1; SMN2PAX8 | |
| Lanatoside C SCHEMBL20582682 | 0.94 | PAX8 (1.00) | MAPTLMNATP53SMN1; SMN2PAX8 | |
| Lanatoside C SCHEMBL44110 | 0.94 | PAX8 (1.00) | MAPTLMNATP53SMN1; SMN2PAX8 | |
| SCHEMBL2518238 | 0.94 | MAPT (0.89) | MAPTLMNATP53SMN1; SMN2PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2137 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102542-A1 | ATPASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NON-NEUROLOGICAL DISORDERS | HAPLO THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | WO | claimed |
| US-20250295693-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2025-09-25 | — | — | US | claimed |
| WO-2025093735-A2 | AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES | DRUG TARGET IP B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| CN-119874798-A | Inhibitor for targeting protein interaction and application thereof | 天津科技大学 | 2025-04-25 | — | — | CN | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| CN-118436665-A | Triterpene structure and analogue thereof and application thereof in preparing antiviral drugs | 浙大城市学院 | 2024-08-06 | — | — | CN | claimed |
| US-20240216411-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2024-07-04 | — | — | US | claimed |
| EP-4387991-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | Julius-Maximilians-Universität Würzburg (DE) | 2024-06-26 | — | — | EP | claimed |
| EP-3654841-B1 | TARGETED OSMOTIC LYSIS OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV (US) | 2024-02-07 | — | — | EP | claimed |
| US-20240025904-A1 | PDE9 INHIBITORS FOR TREATING CARDIAC FAILURE | VANDERBILT UNIVERSITY | 2024-01-25 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |
| US-5545623-A | ADMINISTERING DIGITALIS DERIVATIVES | Matsumori, Akira (JP) | 1996-08-13 | — | — | US | claimed |
| US-5153178-A | Inotropic agent for the heart of a mixture of a glycoside and a protoberberine alkaloid | MAROKO, ROBERT | 1992-10-06 | — | — | US | claimed |
| EP-0056995-B1 | CHEMICAL COMPLEX | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-03-26 | — | — | EP | claimed |
| EP-0108147-A4 | Use of a protoberberine alkaloid and composition containing same. | MAROKO PETER R | 1984-09-13 | — | — | EP | claimed |
| EP-0108147-A1 | Use of a protoberberine alkaloid and composition containing same. | MAROKO PETER R | 1984-05-16 | — | — | EP | claimed |
| WO-1983003970-A1 | COMPOUNDS, COMPOSITIONS AND METHOD OF TREATMENT FOR IMPROVING CIRCULATORY PERFORMANCE | MAROKO PETER R | 1983-11-24 | — | — | WO | claimed |
| EP-0056995-A1 | Chemical complex | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-08-04 | — | — | EP | claimed |
| US-4182330-A | Means for administering amphipathic medicament | ALZA CORPORATION (US) | 1980-01-08 | — | — | US | claimed |